ArticleFrontiers in aging2024
Assessing the utility of epigenetic clocks for health prediction in South Korean.
Article in Frontiers in aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Responsiveness of epigenetic aging biomarkers to longevity interventions in humans.Nature medicine · 2026Article
- The aging paradox of Cushing's syndrome: Stress without clear senescence?Journal of neuroendocrinology · 2026Review
- KoMethylNet: a novel epigenetic clock based on neural network analysis of DNA methylation data and epigenetic age acceleration in a Korean population.BMC medicine · 2025Article
- What's counted counts: the implications of underrepresentation for the application of epigenetic clocks in diverse populations.Clinical epigenetics · 2025Review
- Epigenetic Regulation of Aging and its Rejuvenation.MedComm · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenetic clocks have been developed to track both chronological age and biological age, which is defined by physiological biomarkers and the risk of adverse health outcomes. Epigenetic age acceleration (EAA) has been found to predict various diseases, aging-related factors, and mortality. However, epigenetic clocks have predominantly been developed with individuals of European or Hispanic ancestry, and their association with health outcomes and environmental factors has not been sufficiently assessed in East Asian populations. Here, we investigated nine epigenetic clocks: five trained on chronological age (first-generation) and four on biological age (second-generation), using DNA methylation data from blood samples of South Koreans. EAAs of second-generation epigenetic clocks reflected the risk of chronic diseases (type 2 diabetes and hypertension), levels of health-related blood markers (alanine aminotransferase, aspartate aminotransferase, high density lipoprotein, triglyceride, and high sensitivity C-reactive protein), and lung functions (percentage of predicted FEV1 and percentage of predicted FVC), while EAAs of first generation clocks did not. Using follow-up data, we also found that EAAs of second-generation clocks were associated with the time to onset risks of chronic diseases. Health behavior factors (drinking, smoking, exercise, body mass index, and waist-hip ratio), socioeconomic status (income level and educational attainment), and psychosocial status were associated with EAAs of second-generation clocks, while only smoking status was associated with EAAs of first-generation clocks. We conducted validation analyses in an independent South Korean cohort and replicated the association of EAAs with health outcomes and environmental factors. Age acceleration of epigenetic clocks is influenced by various environmental factors and can serve as an effective predictor of health in South Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.